Drug safety in Mali

Aboubacar Alassane Oumar, Modibo Sangare, Souleymane Fofana, Yacouba Cissoko, Dramane Diallo, Mamoudou Maiga, Mariam Traore, Guida Landoure, Georges Togo, Amadou Kone, Paul Tulkens, Sounkalo Dao, Jean Cyr Yombi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The Malian pharmacovigilance program has been associated with modest growth over the past years. The purpose of this chapter is to assess the current state of pharmacovigilance (PV) in Mali and the adverse drug reactions reported to the National Pharmacovigilance Center of Mali. The profiles and number of adverse drug reactions (ADRs), the degree of toxicity, and the WHO and Naranjo scores are evaluated. We found that three university teaching hospitals in Mali conducted such PV studies. Our results showed that although there is a recognition of the need for PV, the practice was very limited. Only 67.6% of participant practitioners had an accepted knowledge for PV and its methodology. This situation is attributed to the insufficient knowledge about what can or should be reported in PV and a lack of a reliable notification process. Nevertheless, this study highlighted the profile of commonly used ADRs and the problems inherent to systematic reporting.

Original languageEnglish (US)
Title of host publicationDrug Safety in Developing Countries
Subtitle of host publicationAchievements and Challenges
PublisherElsevier
Pages557-568
Number of pages12
ISBN (Electronic)9780128198377
ISBN (Print)9780128204122
DOIs
StatePublished - Jan 1 2020

Keywords

  • Mali
  • Pharmacovigilance
  • adverse drug reaction
  • drug safety

ASJC Scopus subject areas

  • Economics, Econometrics and Finance(all)
  • General Business, Management and Accounting

Fingerprint

Dive into the research topics of 'Drug safety in Mali'. Together they form a unique fingerprint.

Cite this